Alume Biosciences Gains FDA Breakthrough Therapy Designation for Bevonescein
SAN DIEGO, Calif. — September 25, 2026 Alume Biosciences, Inc. announced that the U.S. Food and Drug Administration (FDA)...
Nerve Injury
Advertisement
Consano Bio Announces Peer-Reviewed Nonclinical Research Supporting Therapeutic Potential of C-1101 in Chronic Sciatica
Burlington, Massachusetts, U.S., September 10, 2026 Consano Bio, Inc. has announced the publication of peer-reviewed nonclinical research evaluating C-1101,...
Adagene and Third Arc Bio Select First Lead Candidate
San Diego, California, and Suzhou, China, September 10, 2026 Adagene Inc. and Third Arc Bio, Inc. have announced the...
Consano Bio Gains FDA Fast Track for C-1101
BURLINGTON, Mass., August 18, 2026 Consano Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted...
Advertisement
